BioSyent (CVE:RX) Reaches New 12-Month High – Here’s What Happened

BioSyent Inc. (CVE:RXGet Free Report)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as C$11.74 and last traded at C$11.74, with a volume of 4577 shares trading hands. The stock had previously closed at C$11.25.

BioSyent Stock Performance

The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The company has a 50 day simple moving average of C$11.05 and a 200-day simple moving average of C$10.27. The stock has a market cap of C$135.60 million, a P/E ratio of 19.50 and a beta of 0.93.

BioSyent (CVE:RXGet Free Report) last issued its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting the consensus estimate of C$0.13. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. The firm had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. On average, equities analysts expect that BioSyent Inc. will post 0.6944444 earnings per share for the current fiscal year.

Insider Activity

In other news, insider FAX Capital Corp. sold 230,800 shares of the business’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total value of C$2,566,496.00. Also, Director Seyed Ahmad Ashrafi sold 2,320 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of C$10.95, for a total value of C$25,404.00. In the last quarter, insiders sold 233,720 shares of company stock valued at $2,598,560. Insiders own 33.65% of the company’s stock.

BioSyent Company Profile

(Get Free Report)

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

Recommended Stories

Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.